This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
ReFacto Antihemophilic Factor
Drug Names(s): moroctocog alfa, Refacto AF, Recombinant Coagulation Factor VIII
Description: ReFacto Antihemophilic Factor (Recombinant) is a purified protein produced by recombinantDNA technology for use in therapy of factor VIII deficiency. ReFacto is a glycoprotein with anapproximate molecular mass of 170 kDa consisting of 1438 amino acids. It has an amino acidsequence that is comparable to the 90 + 80 kDa form of factor VIII, and post-translationalmodifications that are similar to those of the plasma-derived molecule. ReFacto has in vitrofunctional characteristics comparable to those of endogenous factor VIII.
Biovitrum and Pfizer
ReFacto was originally developed by Biovitrum's organization while this was part of Pharmacia. The drug was sold to Wyeth in 1997. Biovitrum gains royalties and has co-promotion rights in the Middle East and Nordic regions.
In January 2009, Pfizer and Wyeth announced that they entered into a definitive merger agreement under which Pfizer will acquire Wyeth in a cash-and-stock transaction currently valued at $50.19 per share, or a total of approximately $68 billion. In October 2009, Pfizer completed its acquisition of Wyeth.
In February 2012, Sobi announced that Sobi and Pfizer have extended their supply agreement for ReFacto AF/XYNTHA until 31 December 2020, with an option to be further renewed. The previous agreement was due to expire in 2015. In a separate agreement, Sobi and Pfizer also agreed that Sobi would return the co-promotion rights for ReFacto and BeneFIX in the Nordic region to Pfizer as of 15 February 2012 in exchange for a payment to...See full deal structure in Biomedtracker
Partners: Swedish Orphan Biovitrum
ReFacto Antihemophilic Factor News
Pink Sheet Wyeth’s Xyntha Wins FDA Nod For Hemophilia A
Additional information available to subscribers only: